July 11, 2026
A vaccine for high-grade astrocytomas is delivering promising long-term results, with 66% of patients alive after 8 years and disease progression halted in 42%! This immune-training approach brings renewed hope in the fight against a common brain tumor. 🧠 #BrainTumor #Vaccine #MedicalResearch
Vaccine Against Brain Tumors Shows Promising Long-Term Results: 33 patients with high-grade astrocytomas, the most common form of glioma, received vaccine that trains the immune system to recognize and fight tumor cells. 66% were still alive after 8 years, and in 42%, the disease had not progressed.